FDA issues statement on Eucrisa for eczema In a controlled trial, participants receiving Eucrisa achieved clear or almost clear skin after 28 days of treatment. The FDA has approved Eucrisa ...

The outlook for the PDE4B inhibitors market is changing as this drug class demonstrates significant therapeutic promise in respiratory, dermatologic, and inflammatory diseases. Existing approvals such ...

Please provide your email address to receive an email when new articles are posted on . Median time of flare-free maintenance was 111 days in the crisaborole group vs. 30 days in vehicle group. Those ...

Atopic dermatitis is one of the most common chronic inflammatory skin diseases worldwide and is also the most common form of eczema. Although infants and children are most often affected, adults can ...

Casey Butrus, PharmD: I know we’re talking a lot about topical ruxolitinib, or Opzelura, which is a Janus kinase [JAK] inhibitor. How does this mechanism of action really differ from what else is on ...

Between an unrelenting itch that interrupts sleep and the social challenges of rashes that can appear anywhere on the body without warning, atopic dermatitis has many ways of raising a person’s stress ...

Pune, Nov. 09, 2020 (GLOBE NEWSWIRE) -- The global dermatitis drugs market size will expand considerably in the coming years driven by the advancements across numerous drug classes. According to a ...

Scientists continue to discover treatments for atopic dermatitis, the most common form of the skin condition eczema. They’ve learned that JAK inhibitors, once reserved for other illnesses, also help ...